GlassScriptPhysician profile
Samuel J Recob
NPI 1427218577
$1,485.01
in general payments reported to CMS, 2019-2025
30 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.12 · 2020: $243 · 2021: $321 · 2022: $278 · 2023: $249 · 2024: $127 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.47 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $270.98 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $141.85 | 2021-2023 | |
| Lilly USA, LLC | $118.43 | 2020-2024 | Mounjaro |
| Astellas Pharma US INC | $115.57 | 2023-2025 | Veozah |
| Novo Nordisk INC | $97.23 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $92.16 | 2019-2024 | |
| Pfizer INC. | $74.93 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.65 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $43.59 | 2021-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $42.32 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.01 | 2021-2022 | |
| Radius Health, INC. | $37.70 | 2019-2025 | Tymlos |
| Allergan, INC. | $37.43 | 2020 | |
| Merck Sharp & Dohme LLC | $29.63 | 2021-2022 | |
| Daiichi Sankyo INC. | $29.33 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $29.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.30 | 2023 | Fasenra |
| Philips North America LLC | $19.30 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.83 | 2025 | Caplyta |
| Amarin Pharma, INC. | $18.68 | 2020 | |
| Axsome Therapeutics, INC. | $17.02 | 2022 | |
| Biogen, INC. | $16.76 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.48 | 2022 | |
| Exact Sciences Corporation | $15.97 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $14.96 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.39 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $10.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Recob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.